Pharmaceuticals Industry Trends January 2024

Market Monitor

  • Australia,
  • Belgium,
  • Brazil,
  • Canada,
  • China,
  • Czech Republic,
  • Denmark,
  • Finland,
  • France,
  • Germany,
  • Hong Kong SAR,
  • Hungary,
  • India,
  • Indonesia,
  • Ireland,
  • Italy,
  • Japan,
  • Malaysia,
  • Mexico,
  • Netherlands,
  • New Zealand,
  • Philippines,
  • Poland,
  • Portugal,
  • Singapore,
  • Slovakia,
  • South Korea,
  • Spain,
  • Sweden,
  • Switzerland,
  • Taiwan,
  • Thailand,
  • Turkey,
  • United Arab Emirates,
  • USA,
  • United Kingdom,
  • Vietnam
  • Chemicals/Pharma

16th January 2024

Global output and sales growth pick up in 2024

Global pharmaceuticals output growth slowed to just 0.5% in 2023 - after a whopping 17.3% increase in 2021 and 6.8% in 2022. This spike was driven by the massive production of Covid vaccinations. In 2024, we expect global output and sales to increase by 4.6% and 5.1% respectively, mainly driven by the Asia Pacific region. Vaccine production will continue to support growth, although at a lower level than in previous years.

Producers of speciality products, medicines for chronic conditions and generic drugs will find opportunities for growth among ageing populations. Producers of medication for weight-loss are facing growth predictions of more than USD 75 billion by 2030. Improving access to healthcare within emerging markets will also support pharmaceuticals’ output and sales.

Potential constraints ahead

High inflation and interest rates have been impacting household spending power, leading to lower demand for products such as over-the counter medicines. The need to reduce fiscal deficits and government debt levels is also likely to affect public healthcare spending. Some markets including the EU, US and UK are imposing new or revised drug pricing regulations in a bid to lower state healthcare costs. This is meeting some resistance from the industry, which argues regulated pricing could impact their ability to invest in R&D.

That said, in general the industry has robust equity, solvency and liquidity. Most pharmaceuticals and biotech businesses are able to enjoy good access to external financing to help sustain high R&D expenditures.

Please download the report below to read more about the sector´s outlook in the Americas, Asia-Pacific and Europe.





Related documents


Each publication available on or from our websites, such as, but not limited to webpages, reports, articles, publications, tips and helpful content, trading briefs, infographics, videos (each a “Publication”) is provided for information purposes only and is not intended as a recommen¬dation or advice as to particular transactions, investments or strategies in any way to any reader. Readers must make their own independent decisions, commercial or otherwise, regarding the information provided. While we have made every attempt to ensure that the information contained in any Publication has been obtained from reliable sources, Atradius is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in any Publication is provided ’as is’, with no guarantee of completeness, accuracy, timeliness or of the results obtained from its use, and without warranty of any kind, express or implied. In no event will Atradius, its related partnerships or corporations, or the partners, agents or employees thereof, be liable to you or anyone else for any decision made or action taken in reliance on the information in any Publication, or for any loss of opportunity, loss of profit, loss of production, loss of business or indirect losses, special or similar damages of any kind, even if advised of the possibility of such losses or damages.